295 reports of suspected side effects of implants in 2023 In 2023, 295 individuals reported one or more suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI).
MEBI: 193 reports of suspected side effects of implants in 2022 In 2022, 193 individuals reported suspected side effects of implants to RIVM’s Dutch Reporting Centre for Adverse Effects of Medical Implants (MEBI). Most reports received concerned breast implants, copper IUDs and wrinkle fillers. This is highlighted in MEBI’s annual report.
From 1 October 2023, heel prick test also screens for metabolic disorder ALD From 1 October 2023, the blood of newborn babies will also be tested for the metabolic disorder adrenoleukodystrophy (ALD). This is done with the heel prick screening test.
NIPT available as standard option for all pregnant women from 1 April From 1 April 2023, the Non-Invasive Prenatal Test (NIPT) will be available to all pregnant women. They do not have to take part in a scientific study for this.
Higher alert level for Ebola There is an Ebola outbreak in several regions of Uganda that are also frequented by tourists. RIVM therefore asks medical professionals to be alert to symptoms that could indicate Ebola among people who have travelled to Uganda, and to request diagnostics to rule out or confirm Ebola.
RIVM formulates criteria for R&D of sustainable pharmaceuticals As part of an international research project, RIVM has formulated criteria for R&D of sustainable new pharmaceuticals. These GREENER criteria are an important first step to develop pharmaceuticals that do not impact the environment..
Antibiotic use and antimicrobial resistance remain stable Antibiotic resistance in the Netherlands remained stable in 2021 compared with the five previous years. This is evident from the 2022 annual NethMap/MARAN report.
Can healthy gut microbes protect us against antibiotic-resistant bacteria? It is largely assumed within the scientific community that a healthy intestinal microbiome can provide resistance against the settling, growth and multiplication of antibiotic-resistant bacteria.
New WHO Collaborating Centre hosted by RIVM combines laboratory preparedness and biorisk RIVM has been designated WHO Collaborating Centre for Laboratory Preparedness and Response for High Threat Pathogens and Biorisk by the World Health Organization (WHO).
Sewage treatment workers not more likely to carry antibiotic-resistant bacteria Employees at sewage and wastewater treatment plants in the Netherlands and Germany are not more likely to carry antibiotic-resistant bacteria than other people. Unie van Waterschappen